Applying Strategies from Universal HIV Screening to Birth-Cohort HCV Screening:

Lessons Learned in an Urban Federally Qualified Health Center (FQHC) Network





Conflict of Interest Disclosure

Melissa Kraus Schwarz

The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months:

 Industry-sponsored grant: a Gilead FOCUS grant supports a portion of my salary.





Learning Objectives

- Understand the application of the TEST model to expand HIV and HCV screening.
- Identify barriers in HIV and HCV screening/treatment and strategies to overcome them.
- Discuss the use of data to inform quality improvement.
- Apply lessons learned from ACCESS' testing expansion initiatives to their own projects.





Presentation Overview

Presentation

- ACCESS background
- TEST Model
- HIV testing expansion
 - o Implementation chronology
 - o Lessons learned
- HCV testing expansion

Discussion

- Strategies to overcome barriers to testing expansion
- Using data for quality improvement





About ACCESS




- Network of 35 health centers serving Chicago and surrounding area
- **Recognized Patient-Centered** Medical Home offering comprehensive health care and wraparound services
- Serves predominantly lowincome minority communities with high HIV prevalence
- Ryan White CARE Act-funded HIV services provider for more than 20 years





TEST Model







Testing Integrated in Clinical Workflows

- This is the desired endpoint
- Maximize sustainability
 - o Employ regular staff rather than dedicated testers
 - o Adapt workflows to make testing routine
 - o Minimize stigma
- Supported by EHR Modifications, Systemic Policy Change, and Training/Feedback/QI





HIV

- Alert provider to need for screening
 - o Annual for ages 13-64o One time age 65+
- SmartSet to simplify ordering
 - o Document consent
 - o Order test/link diagnosis
 - Add testing information to After Visit Summary


HCV

- Alert provider to need for screening
 - o One time for patients born 1945-1965
 - o People who inject drugs (PWID)





Number of HIV Tested Ordered by Day by BPA Status



Number of HIV Tested Ordered by Day by BPA Status

- Graph shows the impact of "Hard Stop" BPA implemented to mark the expansion of universal HIV screening


 Hard stop required clinicians to address BPA immediately
 Very unpopular and in place for very short time
 - Replaced by "Soft" BPA that did not have to be addressed during encounter
- Less disruptive Hard Stop activated for World AIDS Day

 Hard stop required to be addressed before closing encounter
 Less disruptive
- Hard Stop activated intermittently to maintain awareness but impact diminishing





HCV Screening by Month by Birth Cohort



HCV Screening by Month by Birth Cohort

- Graph shows impact of implementation of Birth Cohort BPA implemented August 2016
- Marked increase over a few months in number of patients born 1945-1965 screened for HCV
 - o July 2016: 140
 - o August 2016: 405
 - o September 2016: 485
 - o October 2016: 676
 - o November 2016: 1,011
- Soft BPA caused a less dramatic increase in screening than the Hard Stop HIV BPA but less disruptive and no pushback from clinicians





Systemic Policy Change

- BPAs most powerful tool but not sufficient without systemic policy change and leadership support
- Leadership support for lengthy process of integrating testing and linkage to care
 - o 2012 HIV pilot at 7 sites
 - o Universal HIV testing expansion with Hard Stop BPA June 2015
 - o HCV Birth Cohort BPA August 2016
- Modification to general consent to treatment to include HIV screening
- Regional Medical Directors track HIV testing rates by health center, and provider testing rates included in quality metrics





HIV/HCV Testing Expansion Chronology

AUGUST 2013 MILESTONE: Systemwide Epic rollout complete	JUNE 2015 MILESTONE: Hard Stop HIV Testing BPA Deploy Hard Stop HIV Screening BPA for patients age 13-64 not tested for HIV in the prior year or age 65+ never tested Hard stop scon removed due to severe disruption to workflows; "soft" BPA remains in place	AUGUST 2016 MILESTONE: Birth Cohort HCV BPA December 2016 Temporarily reestablish Hard Stop H BPA in observance of World AIDS Dispersional Statement of World AIDS Dispersional Statement (Statement of Statement of	
7-SITE HIV PILOT	EXPANSION OF ROUTINE UNIVERSAL HIV SCREENING	HCV TESTING AND LINKAGE TO CARE EXPANSION	
Assessment of existing HIV testing practices, linkage to care procedures and reporting capabilities Identifying barriers to routine universal screening Building Epic reports to capture HIV and STI testing data Providing training to providers and staff to overcome barriers to screening and linkage to care Produce communication materials for patients ACCESS COMMUNITY HEALTH NETWORK	Education and outreach to providers and staff on rationale for universal testing and new procedures for documenting consent Strengthening linkage to care processes Promote 4th Generation HIV test as the preferred test and add it to system wide favorites list	Continue monitoring HIV testing rates BPA modifications to simplify consent and reduce required number of clicks for HIV testing Education and outreach to providers on recommended HCV screening for 1945-1965 birth cohort January-December 2017 Experiment with sporadic implementation of Hard Stop HIV BPA Refinements to HCV Birth Cohort BPA - quantitative RNA reflex testing Establishment of Hepatitis C workgroup to develop and refine workflows Collaboration with onsite Walgreens pharmacists to assist in completing prior authorization paperwork for HCV treatment Partnership with CORE Center to reserve appointment block for Fibroscans for ACCESS patients Modifications to reports to facilitate HIV and HCV linkage to care workflows and track HCV patients through diagnosis, staging, treatment and cure Primary care providers trained through Project ECHO to treat HC	1

Lessons Learned from HIV Testing Expansion

- EHR modifications are a powerful tool to encourage routine screening
- Gain provider support to communicate the importance of testing within the context of primary care
- Changing testing rates at a population level takes sustained effort and attention over time
- Incorporate monitoring of testing rates into ongoing clinical quality measurement and improvement processes
- Assess and address barriers to testing and linkage to care and provide ongoing training and resources to address those barriers





Training/Feedback/QI


- Initial training for providers on universal HIV screening o Recommended by CDC
 - o Some providers uncomfortable discussing risk behaviors
 - o Information on internal HIV treatment resources and procedures for linkage to care
- Information on HIV BPA
- Monthly feedback for Regional Medical Directors on HIV and STI testing numbers and rates
- Monthly review of HIV and HCV testing metrics by ACCESS' Infectious Disease Quality Committee





Increasing Screening Rates a Long-Term Process


Patients Age 13+ by HIV Screening History








Increasing Screening Rates a Long-Term Process





Increasing Screening Rates a Long-Term Process

Patients Age 13+ by HIV Screening History

- Upward trend lines for percent ever tested for HIV and percent "Up to Date" with recommended annual screening for ages 13-64 and onetime screening for age 65+
 - o Ever Tested: 48% in January 2016 to **70%** in February 2019
 - o Up to Date: 38% in January 2016 to **51%** in February 2019


Birth Cohort Patients by HCV Screening History

- Upward trend in percent of Birth Cohort ever tested for HCV
 - o Started at 19% for birth cohort patients seen in January 2016
 - o Reached **71%** (4,847) for birth cohort patients seen in February 2019





HCV Linkage Rates by Pilot Site



TRANSFORMING COMMUNITY HEALTH CARE

HCV Linkage Rates by Pilot Site


- At two initial pilot sites for linkage navigation 141 of 166 (85%) HCV RNA+ patients linked to care January 2016-February 2019
- At remaining sites 347 of 580 (60%) HCV RNA+ patients linked to care January 2016-February 2019
- Linkage Navigation expanded to 3 more sites in February 2018, linking 21 of 32 (66%) HCV RNA+ patients, about the same as the 64% linked at non-pilot sites during that time

- Overall upward trends for linking HCV RNA+ patients to appointment to initiate staging
- Linkage rates highest at two initial pilot sites with Linkage Navigators
- Linkage Navigators' reach expanded to 3 more sites in 2018
- Linkage rates declined overall in 2018





HCV Linkage by Provider Type







HCV Linkage by Provider Type

- Shows counts of patients testing HCV RNA+ each month who eventually linked with a primary care provider or specialist to initiate HCV staging for treatment
- Substantial fluctuation from month to month
- A number of PCPs completed Project ECHO HCV Treatment Training in 2017, and an increasing number of patients linked with PCP in 2017; that number decreased in 2018 as some trained providers left the organization
- Total 705 HCV RNA+ patients, January 2016 February 2019 o 305 Specialist (avg 8.0/month) o 148 to PCP (avg 5.1/month)
 - o 252 Remained unlinked (avg 6.8/month)






Screening, Diagnosis, and Treatment Stepwise Cascade Percentages and Counts

	Total Percentage 2016-February 20				Total Co 5-Februa		19	
	100% HCV Ab+			1,279 H	CV Ab+			
	83% HCV RNA Tested			1,067 HC	CV RNA Tes	ted		
	66% HCV RNA+			706 HCV	RNA+			
	64% Linked to Care			453 Link	<mark>ed</mark> to Care			
	34% VL Zero After Link	age		154 VL Z	ero After L	inkage		
0	%	100	%	0 4	8 00	00	1,200	





Screening, Diagnosis, and Treatment Stepwise Cascade Percentages and Counts by Year



Screening, Diagnosis and Treatment

- Two sets of graphs showing overall and year-by-year numbers and percentages for the cascade through screening, diagnosis, and treatment.
- Totals: 1,279 HCV Ab+, 1067 (83%) completed RNA test, of whom 706 (66%) were HCV RNA+. Of the RNA+ 453 (64%) linked to care, completing an appointment with an specifically trained PCP or Infectious Disease specialist to initiate staging for HCV. Of those positive, 154 (34% of linked) had one or more subsequent negative HCV RNA tests
- All numbers lowered in 2018 and in previous years reflecting progress in screening the birth cohort.





Discussion

- What are the barriers your organization faces in expanding HIV or HCV screening?
- What strategies can you think of to address them?
- What data do you feel are most valuable for monitoring your HIV or HCV testing efforts?





Melissa Kraus Schwarz

Evaluation Specialist

Access Community Health Network

Melissa.Schwarz@achn.net

312.526.2431



